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Video-Assisted Mediastinoscopy in Superior Vena
Cava Obstruction
To Fear or Not to Fear?
Daniel Pop, MD,* Nicolas Venissac, MD, PhD,* Ahmad S. Nadeemy, MD,*† Patrice Guiraudet, MD,*
and Je´roˆme Mouroux, MD, PhD*
Introduction: We investigate the safety and efficacy of video-
assisted mediastinoscopy (VAM) used for diagnosis of the superior
vena cava syndrome.
Methods: In a 7-year period, we have done 447 VAM for malignant
causes. We have compared, in a retrospective study from a prospec-
tively maintained database, the differences between the groups with
(first group) or without (second group) superior vena cava syndrome
in terms of operative time, preoperative and postoperative compli-
cations, and results of pathologic examination. Statistical differences
between the groups were calculated by 2 test.
Results: Mean operative time for first (31 patients) and second (416
patients) groups was 18 and 34 minutes, respectively (p  0.00).
Mean hospital stay was 1.2 days in both the groups. Mortality rates
for the first and second groups were 0 and 0.5% (p  0.31); major
morbidity rates were 0 and 0.7% (p  0.50); and minor morbidity
rates were 6.4 and 1.7% (p  0.27), respectively. In the superior
vena cava syndrome group, most of the lymph nodes biopsied were
in paratracheal superior sites (81%); histology showed small cell
lung cancer in 51.6%, non-small cell lung cancer in 25.8%, and
lymphoma in 22.6%.
Conclusions: VAM represents an important diagnostic tool in
superior vena cava syndrome. Once decided to be used, we think
that video technique is a good option with high rate of efficacy and
low rates of mortality and morbidity.
Key Words: Superior vena cava obstruction, Video-assisted
mediastinoscopy.
(J Thorac Oncol. 2012;7: 386–389)
The superior vena cava is situated in an almost nondisten-sible compartment. Because of its thin walls and low
homodynamic pressure, obstruction occurs by direct inva-
sion, external compression, or thrombosis. Nowadays, the
majority of cases are of malignant origin, so establishing a
precise diagnosis is very important, and therapy is initiated
without delay. Although a markedly elevated venous pressure
cannot be ignored, the risk of procedures may have been
overestimated in the past. Fear is associated each time, and
hence, invasive procedures are necessary for diagnosis. Con-
trary to preconceptions, the superior vena cava obstruction
(SVCO) is not a contraindication for cervical mediastinosc-
opy.1,2 Recent publications showed that mediastinoscopy is a
reliable technique with good efficacy but still potentially
dangerous.3–8 The advent of video-assisted technology gave
further improvements to the classic technique. The advan-
tages and the risks of video-assisted mediastinoscopy (VAM)
are published in the international literature9–12; but to our
knowledge, no article is found concerning its use in the
SVCO. The purpose of our study is to report our experience
with the use of VAM in SVCO concerning its safety and
efficacy.
MATERIALS AND METHODS
In our practice (single institution), VAM replaced the
standard technique beginning 1998. From 2002, all proce-
dures have been studied prospectively. Since then until De-
cember 2008, 567 patients benefited from VAM for diagnos-
tic and staging purpose. Among them, 31 patients were
identified to have a SVCO (group 1), 416 patients had
malignant causes, and 120 patients had nonmalignant causes.
Before operation, the patients underwent a classic in-
vestigation workup: clinical examination, chest x-ray and
computed tomography (CT) scan, and flexible bronchoscopy
(FB). Bronchial lesion was found in 13 patients, but the
biopsies were negative or inconclusive. For the remaining
patients, fine-needle aspiration (FNA) under CT guidance
was done six times, but the biopsies were negative; the lesion
was not accessible using FNA or biopsy considered danger-
ous in 12 patients. To note, another nine patients had SVCO,
but the diagnosis was made by FB for four patients, FNA for
two patients, anterior mediastinotomy for two patients, video
thoracoscopy for one patient. These patients were excluded
from our study.
VAM was done following a standard technique and
equipment.13 Frozen section analysis was done during sur-
gery, and VAM ended as soon as the pathologist indicated the
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histologic diagnosis. We used the mediastinal lymph node
chart published in 1997.14
We have done a retrospective study from a prospec-
tively maintained database, and we had the institutional
review board approval. Data regarding the clinical records of
the patients, operative time, preoperative and postoperative
complications, and the results of pathologic examination
were collected. To estimate the safety and efficacy of VAM
in the SVCO, we compared this group of patients with the
second group of VAM done for diagnostic or staging purpose
for malignancies (416 patients). Statistical differences be-
tween groups were calculated by 2 test, and p  0.05 was
considered statistically significant.
RESULTS
VAM in SVCO represents only 7.45% (31 of 447
patients) of procedures done for malignancies. The charac-
teristics of patients with SVCO (group 1) are compared with
those without SVCO (group 2) in Table 1.
The following signs and symptoms were recorded:
cervicofacial edema in 25 patients (81%), collateral venous
distension in 22 patients (71%), cough in 10 patients (32%),
dyspnea in 6 patients (19%), and thoracic pain in 5 patients
(16%). Strictly superior vena cava syndrome was present in
16 patients (52%). The severity of symptoms was classified
according to the new grading system15; asymptomatic in 19%
(6 patients), mild in 49% (15 patients), and moderate in 32%
(10 patients). No patients had neurologic signs such as sei-
zure or change of sensorium. The mean time between the
patient’s first symptoms and VAM was approximately 45
days (range 15–90 days).
The uneventful operation happened in all patients.
Mean operative time was 18 minutes (range 10–30 minutes).
Two minor complications occurred, and morbidity rate was
6.4%. One patient experienced the next day after VAM a
wound hematoma that was drained surgically (the source of
bleeding was a small subcutaneous vein). Another patient had
postoperative cardiac arrhythmia (successfully treated with
adapted medication). Histology samples showed lung cancer
in 24 patients: small cell lung cancer (SCLC) in 16 patients,
adenocarcinoma in 4 patients, squamous carcinoma in three
patients, and sarcomatoid cancer in one patient. The other
seven patients had lymphoma: Hodgkin in three patients and
non-Hodgkin in four patients. Mean postoperative stay was
1.2 days (range 1–3 days), and most of the patients (24
patients) left the hospital the next day after VAM. Those two
patients with minor complications needed 1 additional day;
the other prolonged hospital stay patients (five patients) were,
in fact, attempted to be transferred to another hospital for
immediate treatment.
In the second group of VAM without SVCO, the mean
operative time was 34 minutes (range 18–40 minutes). Two
deaths occurred, and mortality rate was 0.5%. The first
patient had cardiac arrest at the induction of anesthesia
(nonrecovered despite active maneuvers; autopsy showed
massive myocardic infarction). The second patient had pul-
monary edema because of cardiac failure in the second
postoperative day (death occurred in the fourth postoperative
day). Three major complications occurred. Two major hem-
orrhages, one from carotid artery and one from innominate
artery, require sternal split for repair. One patient needed
reintubation because of severe respiratory insufficiency.
Seven minor complications occurred. One was a periopera-
tory minor hemorrhage because of a bronchial artery tearing.
After dry gauze pressure, hemostatic clip was effective. The
other six complications were pulmonary embolism, cardiac
arrhythmia, pneumothorax, pleural effusion, pneumonia, and
wound hematoma, all treated efficiently. Total morbidity rate
was 2.4%. Histology samples are shown in Table 1. Mean
postoperative stay was 1.2 days (range 1–5 days).
DISCUSSION
Since the firs description of the SVCO by Hunter16 in
1757, the etiologic spectrum has dramatically changed. Now-
adays, more than 95% of cases are because of intrathoracic
malignancies,17 and the lung cancer is the leading pathology
in more than 3⁄4 of cases. Although the obstruction of the
superior vena cava causes worrisome symptoms and signs, no
evidence exist for life-threatening complications if the venous
system is not relieved. Moreover, even though these symp-
toms regress after therapy, the potency of the vena cava is not
reestablished,3 so efforts should be done to establish tissue
diagnosis.18 Histologic samples can be obtained by lesser
invasive techniques such as bronchoscopy, ultrasound-guided
endoscopy, or CT-guided transthoracic biopsy. However, the
diagnostic yield by these methods is low.7 Moreover, the
pathologists find it difficult to differentiate lymphomas from
SCLC. Even when the diagnosis of lymphoma is established
TABLE 1. Demographic Data of Patients
Group 1 (31) Group 2 (416) p
Gender (M/F) 20/11 275/141 NS
Age (yr), median (range) 60 (26–78) 62 (23–80) NS
Site of biopsy (%)
2L 0 25 (6) 0.3434
2R 25 (81) 100 (24) 0.0001
4L 0 154 (37) 0.0017
4R 6 (19) 333 (80) 0.0013
7 0 196 (47) 0.0003
Histopathology (%)
NSCLC 8 (25.8) 347 (83.4) 0.0038
SCLC 16 (51.6) 34 (8.3) 0.0001
Lymphoma 7 (22.6) 25 (5.9) 0.0073
Metastasis 0 10 (2.4) 0.8206
Complication, n (%)
Mortality 0 2 (0.5) 0.3117
Major 0 3 (0.7) 0.5023
Minor 2 (6.4) 7 (1.7) 0.2701
VAM mean time (min) 18 34 0.0001
Hospital stay (d) 1.2 1.2 NS
M, male; F, female; NSCLC, non-small cell lung cancer; SCLC, small cell lung
cancer; VAM, video-assisted mediastinoscopy; NS, not significant.
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with these techniques, surgical biopsy is required for its
characterization with consecutive-specific therapy.7,8
Like all other invasive procedures, VAM has its spe-
cific mortality and morbidity. A good balance between ben-
efits and risks is supported by several arguments. The patients
with SVCO had altered prognosis more by histology than by
the obstructed vein. We could think at life-threatening com-
plications, such as laryngeal or cerebral edema because of an
important mechanical conflict in the area increasing the
venous pressure: tumor and SVCO, oral intubation, and
pretracheal working plane for VAM. The modern series of
cervical mediastinoscopy reported no such complications
after cervical mediastinoscopy.
The main purpose of our study was to determine the
impact of video-assisted technique in this particular set of
patients with SVCO. The advantages are largely exposed in
the international literature.9–12 Our study showed important
differences using VAM. In case of SVCO, despite careful and
slow dissection, the operative time is shorter. The sites of
biopsies are quickly encountered; most of our biopsies are
made in the high level of the paratracheal nodes in 81% of the
cases. The frozen section is quickly available, so no further
biopsies are made. Exact mediastinal lymph node mapping is
not needed, even for non-SCLC (view the mediastinal in-
volvement, the tumor is nonresectable in first intention).
Finally, VAM for SVCO needs 18 minutes, and VAM for
diagnostic or staging purpose needs 34 minutes (mean oper-
ative times).
Several precautions can be taken before, during, and
after VAM. The patient is usually in dorsal decubitus, but the
head and trunk can be slightly elevated to minimize the effect
of gravity in the cephalic venous pressure. The venous access
should be always in the inferior vena cava system. Steroids
can help preoperatively to reduce the upper body edema or
postoperative inflammatory phenomena. During surgery, the
incision can be made carefully, and the superficial veins are
retracted than ligated and divided. The dissection is carried
on in the midline, down to the tracheae, with a small proba-
bility to cross dilated veins. If any doubt exists, needle
punction can be made but usually, the masses do not bleed
excessively. Hemostatic clips can be used largely, and hemo-
static gauze can be effective. From our experience, VAM
technique for SVCO (like VAM without SVCO) does not
require drainage.
Morbidity and mortality because of mediastinoscopy is
very low. In more than 20,000 cases collected by Kirschner,1
the mortality rate is less than 0.5%, and the morbidity rate is
less than 2.5%. Is VAM better? In a recent publication,10
video-assisted technique showed significant improvement in
terms of accuracy, and fewer complications were noted. We
can fear that the presence of SVCO is potentially dangerous,
but in our series, mortality rate is 0% in VAM for SVCO
(VAM without SVCO, a mortality rate of 0.5% was found, but
not specific to the surgery). From our experience, there was no
major event during VAM for SVCO. Minor complication ar-
rived with an accepted rate of 6.4%, but once again only one
related to the surgery. Anyhow our results show no statistical
differences between the two groups of VAM, and the presence
of SVCO did not increase the rate of complications.
A systematic review of a large series of patients (min-
imum five patients) where mediastinoscopy was used for
SVCO is listed in Table 2. Although VAM was introduced in
the clinical setting only recently,30 it is difficult to assess
which author did really use this technique. Moreover, looking
at the study periods of the listed articles, few patients were
benefiting from VAM, so the complication rates are related to
TABLE 2. Literature Review of the Morbidity and Efficacy of Cervical Mediastinoscopy in SVCO
Author Year Period SVCO (n) CM (n)
Complications,
(Major/Minor) Efficacy (%)
Schraufnagel et al.19 1981 1961–1979 107 14 1/1 71
Lewis et al.20 1981 1966–1980 29 15 0/0 100
Painter and Karpf21 1983 1965–1980 56 9 2/3 78
Ahmann3 1984 1953–1981 843 53 3/NR NR
Gamondes et al.22 1985 1977–1983 12 12 0/0 75
Vanderhoeft23 1985 1964–1984 93 93 3/0 76
Little et al.24 1985 1960–1985 42 7 0/NR 82
Sculier et al.25 1986 1976–1983 55 19 0/NR NR
Yellin et al.26 1990 1972–1987 63 15 0/1 93
Callejas et al.27 1991 1985–1989 8 8 1/1 100
Bigsby et al.28 1993 1987–1992 18 7 0/2 100
Jahangiri and Goldstraw4 1995 1982–1993 44 34 1/0 97
Fernandez et al.29 1996 1986–1996 22 22 1/0 100
Gamez Garcia et al.5 1997 1974–1995 29 23 0/5 83
Mineo et al.6 1999 1974–1997 111 80 1/4 100
Porte et al.7 2000 1985–1998 88 23 1/4 91
Dosios et al.8 2005 1976–2004 39 18 2/4 97
Total — — 1659 452 14/2539 89.5
Our study 2008 2002–2008 40 31 0/3 100
SVCO, superior vena cava obstruction; CM, cervical mediastinoscopy; NR, not recorded.
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conventional mediastinoscopy. A total of 483 mediastinosco-
pies were noted (Table 2). Mortality rate was 0.4%. Major
morbidity rate was calculated to 2.9% and a minor morbidity
rate to 5.2%, for a total of 8.1%. In our experience, we had no
mortality and no major morbidity and an acceptable rate of
minor complications.
The efficacy rate of mediastinoscopy in establishing the
diagnosis is 71 to 100% (average of 89.5%). Our rate is
100%. Perhaps, the most important point is not the efficacy of
mediastinoscopy in SVCO but to choose the appropriate
diagnostic procedure. Is not surprising that algorithm is
proposed,7,28 and the better candidate is the patient with the
lesions situated around the tracheal tree from the experience
we had, for the study period, 40 patients with SVCO. Besides
the 31 VAM patients, the others had the diagnosis made by
FB or FNA, anterior mediastinotomy, and video-assisted
thoracoscopy. The key is the exact choice of the technique in
function of a cornerstone CT scan along with the clinical
history. Recently, ultrasonographic assistance was made with
VAM.31 For instance, it seems that along with a better
accuracy, no operative mortality and morbidity was noted.
The only difference is the operative time, which is longer
than our times. This new technique is understudy, so further
investigation is necessary.
In conclusion, VAM represents an important diagnostic
tool in superior vena cava syndrome. Once decided to be
used, we think that video technique is a better option in terms
of accuracy, mortality, and morbidity compared with conven-
tional mediastinoscopy.
ACKNOWLEDGMENTS
The authors thank Mrs. Camelia Roatis, BSc, PChem
(Senior Analyst, Trace Organics) from Maxxam Analytics,
Calgary, Alberta, Canada, for her help in the translation
process.
REFERENCES
1. Kirschner PA. Cervical mediastinoscopy. Chest Surg Clin N Am 1996;
6:1–20.
2. Lochridge SK, Knibbe WP, Doty DB. Obstruction of the superior vena
cava. Surgery 1979;85:14–24.
3. Ahmann R. A reassessment of the clinical implications of the superior
vena caval syndrome. J Clin Oncol 1984;2:961–969.
4. Jahangiri M, Goldstraw P. The role of mediastinoscopy in superior vena
caval obstruction. Ann Thorac Surg 1995;59:453–455.
5. Gamez Garcia AP, Martin de Nicolas Serrahima JL, Marro´n Ferna´ndez
C, et al. [Surgical diagnostic procedures in superior vena cava syn-
drome]. Arch Bronconeumol 1997;33:284–288.
6. Mineo TC, Ambrogi V, Nofroni I, et al. Mediastinoscopy in superior
vena cava obstruction: analysis of 80 consecutive patients. Ann Thorac
Surg 1999;68:223–226.
7. Porte H, Metois D, Finzi L, et al. Superior vena cava syndrome of
malignant origin. Which surgical procedure for which diagnosis? Eur
J Cardiothorac Surg 2000;17:384–388.
8. Dosios T, Theakos N, Chatziantoniou C. Cervical mediastinoscopy and
anterior mediastinotomy in superior vena cava obstruction. Chest 2005;
128:1551–1556.
9. Venissac N, Alifano M, Mouroux J. Video-assisted mediastinoscopy:
experience from 240 consecutive cases. Ann Thorac Surg 2003;76:208–
212.
10. Leschber G, Sperling D, Klemme W, et al. Does video-mediastinoscopy
improve the results of conventional mediastinoscopy? Eur J Cardiotho-
rac Surg 2008;33:289–293.
11. Witte B, Wolf M, Hurtgen M, et al. Video-assisted mediastinoscopic
surgery: clinical feasibility and accuracy of mediastinal lymph node
staging. Ann Thorac Surg 2006;82:1821–1827.
12. Lemaire A, Nikolic I, Petersen T, et al. Nine-year single center experi-
ence with cervical mediastinoscopy: complications and false negative
rate. Ann Thorac Surg 2006;82:1185–1190.
13. Venissac N, Alifano M, Karimdjee BS, et al. Video-mediastinoscopy in
management of patients with lung cancer: a preliminary study. Surg
Laparosc Endosc Percutan Tech 2000;10:71–75.
14. Mountain CF, Dresler CM. Regional lymph node classification for lung
cancer staging. Chest 1997;111:1718–1723.
15. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome—a
proposed classification system and algorithm for management. J Thorac
Oncol 2008;8:811–814.
16. Hunter W. History of aneurysm of the aorta with some remarks on
aneurysm in general. Med Obser Inq 1757;1:323–357.
17. Macchiarini P. Superior vena cava obstruction. In Patterson GA, Cooper
JD, Deslauriers J, et al. (Eds.), Pearson’s Thoracic and Esophageal
Surgery, 3rd Ed. Philadelphia, PA: Churchill Livingston, 2008. Pp.
1684–1696.
18. Mehta MP, Kinsella TJ. In Shields TW, LoCicero J III, Ponn RB (Eds.)
General Thoracic Surgery, 5th Ed. Philadelphia, PA: Lippincott Wil-
liams & Wilkins, 2000. Pp. 2149–2166.
19. Schraufnagel DE, Hill R, Leech JA, et al. Superior vena caval obstruc-
tion: it is a medical emergency? Am J Med 1981;70:1169–1174.
20. Lewis RJ, Sisler GF, Mackenzie JW. Mediastinoscopy in advanced
superior vena cava obstruction. Ann Thorac Surg 1981;32:458–462.
21. Painter TD, Karpf M. Superior vena cava syndrome: diagnostic proce-
dures. Am J Med Sci 1983;285:2–6.
22. Gamondes JP, Vincent M, Weynants P, et al. [Mediastinoscopy and the
superior vena cava compression or obstruction syndrome. A propos of
12 cases]. Ann Chir 1985;39:482–485.
23. Vanderhoeft P. [Mediastinoscopy in superior vena cava syndrome]. Ann
Chir 1985;7:521.
24. Little AG, Colomb HM, Ferguson MK. Malignant superior vena cava
obstruction reconsidered: the role of diagnostic surgical intervention.
Ann Thorac Surg 1985;40:285–288.
25. Sculier JP, Evans WK, Feld R. Superior vena caval obstruction syn-
drome in small cell lung cancer. Cancer 1986;57:847–851.
26. Yellin A, Rosen A, Reichert N, et al. Superior vena cava syndrome. Am
Rev Respir Dis 1990;141:1114–1118.
27. Callejas MA, Rami R, Catalan M, et al. Mediastinoscopy as an emer-
gency diagnostic procedure in superior vena cava syndrome. Scand
J Thorac Cardiovasc Surg 1991;25:137–139.
28. Bigsby R, Greengrass R, Unruh H. Diagnostic algorithm for acute
superior vena cava obstruction. J Cardiovasc Surg 1993;34:347–350.
29. Fernandez A, Bamman RH, Filomeno LTB. Mediastinoscopy in ad-
vanced superior vena cava syndrome. Lymphology 1996;29(Suppl):
375S–378S.
30. Sortini A, Navara G, Santini M, et al. Video-assisted mediastinoscopy:
a new application of television technology in surgery. Minerva Chir
1994;49:803–805.
31. Pompeo E, Tacconi F, Marino M, et al. Ultrasonography-assisted vid-
eomediastinoscopy in superior vena cava obstruction. J Thorac Cardio-
vasc Surg 2006;133:750–751.
Journal of Thoracic Oncology • Volume 7, Number 2, February 2012 Video-Assisted Mediastinoscopy in SVCO
Copyright © 2012 by the International Association for the Study of Lung Cancer 389
